Summary

Cancer(tumor) profiling is the technology oncologists use to determine if the pathways of a patient's tumor match up with available targeted treatments. Tumor profiling starts with obtaining a sample of tumor tissue. The tissue is usually collected through a core biopsy, but it can also be taken during surgery.
The global market for Cancer (Tumor) Profiling was estimated to be worth US$ 9265 million in 2023 and is forecast to a readjusted size of US$ 19410 million by 2030 with a CAGR of 11.2% during the forecast period 2024-2030
Surging cancer prevalence across the globe is one of the major factors contributing to the market growth. Cancer is the second leading cause of death worldwide. One in six deaths worldwide is due to cancer. In middle- and lower-class economies, 70% of deaths are due to cancer. This expands the growth scope of the market. Surging public-private funding of targeted research activities, emergence of cancer profiling relative to traditional methods of cancer diagnosis, increasing geriatric population base, and increasing product innovation and development due to technological advancements across the world will provide lucrative opportunities for market players. Estimated period 2022-2029. In addition, the surge in the number of strategic cooperations, rising Internet penetration, increasing number of hospitals and laboratories, increasing cases of lung cancer, prostate cancer, and acute leukemia, and increasing healthcare expenditure per capita will lead to further expansion of the market growth rate in the future.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer (Tumor) Profiling, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cancer (Tumor) Profiling by region & country, by Type, and by Application.
The Cancer (Tumor) Profiling market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer (Tumor) Profiling.

Market Segmentation
By Company
Illumina
Qiagen
Neogenomics Laboratories
HTG Molecular Diagnostics
Genomic Health
Caris Life Sciences
Helomics Corporation
Nanostring Technologies
Oxford Gene Technology
Ribomed Biotechnologies
Segment by Type:
Immunoassay
NGS
Mass Spectrometry
Others
Segment by Application
Clinical
Research
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cancer (Tumor) Profiling manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Cancer (Tumor) Profiling in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Cancer (Tumor) Profiling in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Cancer (Tumor) Profiling Product Introduction
1.2 Global Cancer (Tumor) Profiling Market Size Forecast
1.3 Cancer (Tumor) Profiling Market Trends & Drivers
1.3.1 Cancer (Tumor) Profiling Industry Trends
1.3.2 Cancer (Tumor) Profiling Market Drivers & Opportunity
1.3.3 Cancer (Tumor) Profiling Market Challenges
1.3.4 Cancer (Tumor) Profiling Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cancer (Tumor) Profiling Players Revenue Ranking (2023)
2.2 Global Cancer (Tumor) Profiling Revenue by Company (2019-2024)
2.3 Key Companies Cancer (Tumor) Profiling Manufacturing Base Distribution and Headquarters
2.4 Key Companies Cancer (Tumor) Profiling Product Offered
2.5 Key Companies Time to Begin Mass Production of Cancer (Tumor) Profiling
2.6 Cancer (Tumor) Profiling Market Competitive Analysis
2.6.1 Cancer (Tumor) Profiling Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Cancer (Tumor) Profiling Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer (Tumor) Profiling as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Immunoassay
3.1.2 NGS
3.1.3 Mass Spectrometry
3.1.4 Others
3.2 Global Cancer (Tumor) Profiling Sales Value by Type
3.2.1 Global Cancer (Tumor) Profiling Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cancer (Tumor) Profiling Sales Value, by Type (2019-2030)
3.2.3 Global Cancer (Tumor) Profiling Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Clinical
4.1.2 Research
4.2 Global Cancer (Tumor) Profiling Sales Value by Application
4.2.1 Global Cancer (Tumor) Profiling Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cancer (Tumor) Profiling Sales Value, by Application (2019-2030)
4.2.3 Global Cancer (Tumor) Profiling Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Cancer (Tumor) Profiling Sales Value by Region
5.1.1 Global Cancer (Tumor) Profiling Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cancer (Tumor) Profiling Sales Value by Region (2019-2024)
5.1.3 Global Cancer (Tumor) Profiling Sales Value by Region (2025-2030)
5.1.4 Global Cancer (Tumor) Profiling Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Cancer (Tumor) Profiling Sales Value, 2019-2030
5.2.2 North America Cancer (Tumor) Profiling Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Cancer (Tumor) Profiling Sales Value, 2019-2030
5.3.2 Europe Cancer (Tumor) Profiling Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Cancer (Tumor) Profiling Sales Value, 2019-2030
5.4.2 Asia Pacific Cancer (Tumor) Profiling Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Cancer (Tumor) Profiling Sales Value, 2019-2030
5.5.2 South America Cancer (Tumor) Profiling Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Cancer (Tumor) Profiling Sales Value, 2019-2030
5.6.2 Middle East & Africa Cancer (Tumor) Profiling Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cancer (Tumor) Profiling Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cancer (Tumor) Profiling Sales Value
6.3 United States
6.3.1 United States Cancer (Tumor) Profiling Sales Value, 2019-2030
6.3.2 United States Cancer (Tumor) Profiling Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cancer (Tumor) Profiling Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cancer (Tumor) Profiling Sales Value, 2019-2030
6.4.2 Europe Cancer (Tumor) Profiling Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cancer (Tumor) Profiling Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cancer (Tumor) Profiling Sales Value, 2019-2030
6.5.2 China Cancer (Tumor) Profiling Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cancer (Tumor) Profiling Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cancer (Tumor) Profiling Sales Value, 2019-2030
6.6.2 Japan Cancer (Tumor) Profiling Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cancer (Tumor) Profiling Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cancer (Tumor) Profiling Sales Value, 2019-2030
6.7.2 South Korea Cancer (Tumor) Profiling Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cancer (Tumor) Profiling Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cancer (Tumor) Profiling Sales Value, 2019-2030
6.8.2 Southeast Asia Cancer (Tumor) Profiling Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cancer (Tumor) Profiling Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cancer (Tumor) Profiling Sales Value, 2019-2030
6.9.2 India Cancer (Tumor) Profiling Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cancer (Tumor) Profiling Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Illumina
7.1.1 Illumina Profile
7.1.2 Illumina Main Business
7.1.3 Illumina Cancer (Tumor) Profiling Products, Services and Solutions
7.1.4 Illumina Cancer (Tumor) Profiling Revenue (US$ Million) & (2019-2024)
7.1.5 Illumina Recent Developments
7.2 Qiagen
7.2.1 Qiagen Profile
7.2.2 Qiagen Main Business
7.2.3 Qiagen Cancer (Tumor) Profiling Products, Services and Solutions
7.2.4 Qiagen Cancer (Tumor) Profiling Revenue (US$ Million) & (2019-2024)
7.2.5 Qiagen Recent Developments
7.3 Neogenomics Laboratories
7.3.1 Neogenomics Laboratories Profile
7.3.2 Neogenomics Laboratories Main Business
7.3.3 Neogenomics Laboratories Cancer (Tumor) Profiling Products, Services and Solutions
7.3.4 Neogenomics Laboratories Cancer (Tumor) Profiling Revenue (US$ Million) & (2019-2024)
7.3.5 HTG Molecular Diagnostics Recent Developments
7.4 HTG Molecular Diagnostics
7.4.1 HTG Molecular Diagnostics Profile
7.4.2 HTG Molecular Diagnostics Main Business
7.4.3 HTG Molecular Diagnostics Cancer (Tumor) Profiling Products, Services and Solutions
7.4.4 HTG Molecular Diagnostics Cancer (Tumor) Profiling Revenue (US$ Million) & (2019-2024)
7.4.5 HTG Molecular Diagnostics Recent Developments
7.5 Genomic Health
7.5.1 Genomic Health Profile
7.5.2 Genomic Health Main Business
7.5.3 Genomic Health Cancer (Tumor) Profiling Products, Services and Solutions
7.5.4 Genomic Health Cancer (Tumor) Profiling Revenue (US$ Million) & (2019-2024)
7.5.5 Genomic Health Recent Developments
7.6 Caris Life Sciences
7.6.1 Caris Life Sciences Profile
7.6.2 Caris Life Sciences Main Business
7.6.3 Caris Life Sciences Cancer (Tumor) Profiling Products, Services and Solutions
7.6.4 Caris Life Sciences Cancer (Tumor) Profiling Revenue (US$ Million) & (2019-2024)
7.6.5 Caris Life Sciences Recent Developments
7.7 Helomics Corporation
7.7.1 Helomics Corporation Profile
7.7.2 Helomics Corporation Main Business
7.7.3 Helomics Corporation Cancer (Tumor) Profiling Products, Services and Solutions
7.7.4 Helomics Corporation Cancer (Tumor) Profiling Revenue (US$ Million) & (2019-2024)
7.7.5 Helomics Corporation Recent Developments
7.8 Nanostring Technologies
7.8.1 Nanostring Technologies Profile
7.8.2 Nanostring Technologies Main Business
7.8.3 Nanostring Technologies Cancer (Tumor) Profiling Products, Services and Solutions
7.8.4 Nanostring Technologies Cancer (Tumor) Profiling Revenue (US$ Million) & (2019-2024)
7.8.5 Nanostring Technologies Recent Developments
7.9 Oxford Gene Technology
7.9.1 Oxford Gene Technology Profile
7.9.2 Oxford Gene Technology Main Business
7.9.3 Oxford Gene Technology Cancer (Tumor) Profiling Products, Services and Solutions
7.9.4 Oxford Gene Technology Cancer (Tumor) Profiling Revenue (US$ Million) & (2019-2024)
7.9.5 Oxford Gene Technology Recent Developments
7.10 Ribomed Biotechnologies
7.10.1 Ribomed Biotechnologies Profile
7.10.2 Ribomed Biotechnologies Main Business
7.10.3 Ribomed Biotechnologies Cancer (Tumor) Profiling Products, Services and Solutions
7.10.4 Ribomed Biotechnologies Cancer (Tumor) Profiling Revenue (US$ Million) & (2019-2024)
7.10.5 Ribomed Biotechnologies Recent Developments
8 Industry Chain Analysis
8.1 Cancer (Tumor) Profiling Industrial Chain
8.2 Cancer (Tumor) Profiling Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cancer (Tumor) Profiling Sales Model
8.5.2 Sales Channel
8.5.3 Cancer (Tumor) Profiling Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer